


Supplemental figure 2: Patient disposition**Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial**

T-VEC, talimogene laherparepvec.